NCT03739801 |
MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma |
Locally Advanced Unresectable Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Unresectable Gastric Adenocarcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma |
Drug: Liposomal Irinotecan|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Biological: Ramucirumab |
University of Southern California|National Cancer Institute (NCI)|Ipsen |
Phase 1
Phase 2 |
NCT03794973 |
Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN) |
Diabetes Mellitus, Type 1 |
Biological: TOL-3021|Other: TOL-3021 Placebo |
Tolerion, Inc. |
Phase 2 |
NCT03776864 |
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
Hodgkin's Lymphoma |
Biological: Pembrolizumab|Drug: Umbralisib |
University of Washington|National Cancer Institute (NCI) |
Phase 2 |
NCT03637803 |
MRx0518 and Pembrolizumab Combination Study |
Oncology|Solid Tumor|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Melanoma|Bladder Cancer |
Drug: MRx0518|Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] |
4D pharma plc|Merck Sharp & Dohme Corp. |
Phase 1 |
NCT03614949 |
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer |
Cervical Cancer|Cervical Cancer Recurrent|Cervical Cancer Metastatic |
Radiation: Stereotactic body radiation therapy (SBRT)|Drug: Atezolizumab |
H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc. |
Phase 2 |
NCT03704467 |
Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine Diphosphate Ribose [ADP]-Ribose) Polymerase Inhibitor (PARPi)-Resistant Recurrent Ovarian Cancer |
Ovarian Cancer |
Drug: M6620|Drug: Avelumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Gemcitabine|Drug: Bevacizumab |
EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono |
Phase 2 |
NCT03706079 |
Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma |
Asthma |
Biological: Tezepelumab|Other: Placebo |
AstraZeneca|Amgen |
Phase 3 |